The outcome for ALL relapsing after BM transplantation (BMT) remains poor. International Bone Marrow Transplant Register data suggest that about 30% of patients can be cured with a second BMT and that younger age ( o20 years), longer interval between transplants (46 months) and deeper molecular remission contribute to greater likelihood of success. 1 The selection of chemotherapy to achieve deep remission before second BMT is often complicated by the patient's previous exposures to agents with cumulative toxicities such as anthracyclines and/or slow minimal residual disease (MRD) responses to previous induction therapy. The use of novel therapies targeted to specific ALL biology is attractive and has been pioneered for tyrosine kinase inhibitors in Ph-like ALL. 2 Although integrated genomic analysis may identify novel treatment options for relapsed ALL, it is important to establish if targeted therapy will be more effective than conventional remission induction which works in 60-70% of cases. Xenograft models accurately reproduce ALL in preclinical studies and patient-derived xenografts (PDX) could be used to assess this and to prioritize therapy for individual ALL relapse cases. We demonstrate that biologic, genetic and expression analyses combined with the treatment of a patient's ALL in PDX mice were able to provide relevant information in time to guide therapy selection for a patient with a post-transplant relapse resulting in a complete molecular remission and enabling a second BMT.
A 3-year-old girl diagnosed with pre-B-ALL was treated as a high standard-risk patient following the Children's Oncology Group protocol (ALL0331) due to a slow early marrow response with high minimal residual disease (MRD410 ) pre-BMT and a second isolated BM relapse occurred 15 months after the first transplant.
The family wished to pursue curative therapy, with the plan to induce a third remission followed by a second BMT. Treatment with fludarabine, cytarabine and mitoxantrone (FLAG-M) was commenced 5 days after the second relapse ( Figure 1 , Table 1 ). A multi-disciplinary panel was convened to determine whether alternate treatment(s) could be identified and validated in real-time in the event of failure of FLAG-M to achieve a third remission. The panel reviewed diagnostic information, results from the literature and the Pediatric Preclinical Testing Program (PPTP) and chose targeted genetic analyses to be performed to facilitate rapid analysis and enable PDX validation. In particular we tested for a BCR-ABL1-like expression signature including specific targetable fusions, 4 performed phospho-flow cytometry for targetable kinase activity; low-density genomic analysis by multiplex ligation-dependent PCR (MLPA); and screened for activating RAS or JAK mutations. 4, 5 Twenty non-irradiated, immune-deficient, NOD/SCID/IL-2 receptor gamma
tm1Wjl /SzJ, NSG) mice were inoculated by tail vein injection 8 days after the 2nd relapse with 2 × 10 6 BM cells (from the 2nd relapse) to establish the PDX. ). Refractory leukemia was documented on recovery from FLAG-M chemotherapy on day 47 post 2nd relapse. Following topotecanbased treatment MRD fell to 3 × 10 − 2 on day 78 post 2nd relapse. Following a 2nd course of topotecan, MRD was undetectable 119 days after the 2nd relapse and remained negative until 259 days after the 2nd relapse. A third relapse was documented 287 days after the 2nd relapse. A further molecular remission was achieved with additional topotecan-based therapy (MRD negative 406 days after the 2nd relapse). Additional topotecan-based therapy has kept the ALL under control until rising MRD was detected again 601 days after the 2nd transplant.
Results were reviewed 27 days after the 2nd relapse ( Table 1) . Immunophenotyping of the second relapse sample confirmed pre-B-ALL with high CD19 expression. The karyotype was complex including t(17;20)(q21;q11.2) and the potential involvement of RARA locus was confirmed by RAR-α overexpression on Q-PCR (Supplementary Table S2 ). MLPA analysis showed heterozygous deletion of JAK2 exon 23, homozygous deletion of CDNK2A and B, and diploid copy number for EBF1, IKZF1, PAX5, ETV6, BTG1, RB1 and CRLF2 (Supplementary Table S3 ). The targeted analyses were negative for the known KRAS or NRAS mutations 5 and negative for fusions and mutations in JAK1 and JAK2. 4 Gene expression profiling for a BCR-ABL1-like signature showed no overexpression of CRLF2, PDGFRB, ABL1, ABL2 or EPOR. No increase in pSTAT5, pCRKL, pERK, pAKT or total pTyr phosphorylation was demonstrated by phospho-flow cytometry. Apart from CD19 expression and RAR-α overexpression, the molecular analyses did not identify therapeutic targets.
The review of data, PPTP results and the literature identified four therapies for evaluation in the patient's PDX: topotecan, SAR3419, bortezomib and all trans-retinoic acid (ATRA). ATRA was chosen based on t(17;20)(q21;q11.2) and RAR-α overexpression and its clinical effectiveness in patients with acute promyelocytic leukemia. SAR3419 is one of several agents for ALL with CD19 cell-surface expression. SAR3419 was effective in the PPTP ALL panel. 7 Topotecan and bortezomib were chosen primarily for their activity against the PPTP ALL panel 8, 9 and relapsed ALL. 10, 11 Mouse engraftment was detected 48 days after the 2nd relapse and 5 mouse PDX cohorts were treated with SAR3419, ATRA, topotecan, bortezomib or control injection vehicle, starting 53 days after relapse. Treatment of mice was commenced when the proportion of human leukemia cells in the murine peripheral blood exceeded 1%, as we have previously shown that this level of engraftment represents a considerable overall disease burden in the animals. 12 PDX responses were assessed weekly by measuring the percentage of circulating human leukemia cells in mouse peripheral blood. PDX mice treated with SAR3419 and topotecan showed clearance of ALL from the peripheral blood at the end of the 1st week of treatment, 60 days after the 2nd relapse ( Table 1) .
The patient's FLAG-M treatment was complicated by fever, neutropenia, Bacillus cereus infection, possible pulmonary fungal infection and rotavirus gastroenteritis requiring hospitalization and delaying her therapy. On recovery, a frank discussion was held to consider palliation, topotecan-based or alternative chemotherapies. Topotecan-based therapy was offered based on the early xenograft response, supporting PPTP data 8 and activity in relapsed ALL. 10 The family agreed to topotecan treatment 10 which commenced 61 days after the 2nd relapse. A BM examination 27 days later demonstrated a morphologic remission with reduced, but high MRD (Table 1, Figure 1 ). Since the topotecan was well-tolerated by the patient, and achieved excellent disease control in the PDX (Table 1, Supplementary  Table S4 ), a second course was given to reduce MRD levels prior to transplant, resulting in molecular remission (negative MRD) at day 119 (Table 1 , Figure 1) . The patient received a 2nd matchedsibling-donor BMT 145 days after the 2nd relapse. Neutrophil engraftment occurred on day+18 and the patient was discharged on day+26 post BMT. MRD (1 × 10 − 3 ) was detected at 16 weeks ) 47 days from the third relapse. After further topotecan-based chemotherapy, a complete molecular remission was documented 119 days after the 3rd relapse and was maintained until rising MRD was detected 314 days after the 3rd relapse ( Figure 1 ).
This case is of importance for patients with refractory, relapsed ALL. It demonstrated that an alternative treatment could be identified and validated in a PDX in a clinically applicable time frame. This approach is predicated on the capacity to create a PDX model and rapid engraftment of patient cells. The choice and number of therapeutic agents to validate was limited by mouse numbers and timely engraftment may not be possible in all patients. Recent integrated genomic and expression analyses have identified genetic alterations in activating targetable kinases, cytokine receptor signaling or CRLF2 rearrangement expression patterns potentially targetable with currently available therapies 4 but many patients will not have them. 4 Xenograft modeling has been extensively used in the preclinical evaluation of novel therapies 6 but to date has not been applied for treatment selection in individual patients. Evidence suggests that the clonal composition of human ALL continues to evolve to a varying extent following engraftment into immuno-deficient mice. 6, 13, 14 Because the clonal architecture of the PDX was not compared with the patient biopsy in this study it remains possible that the composition of each may be different. However, our primary goal, to provide a treatment recommendation that could be used in the event of conventional therapy failure, was achieved. Two potentially targetable abnormalities, CD19 cell-surface expression and a t(17;20)(q21;q11.2) associated with RAR-αoverexpression, were identified. One targeted therapy, SAR3419 was effective in the PDX, whereas ATRA was not. Although effective in PDX, we were not able to access a CD19-targeted therapy for this patient. Our agent selection for PDX testing, topotecan and bortezomib, was biased towards agents tested in the PPTP ALL xenograft panel with supporting pediatric trial data. [8] [9] [10] [11] We acknowledge that additional agents could have been tested if greater PDX numbers had been available. The PDX-validated topotecan activity, whereas bortezomib was less effective. PDX treatment data were available at the point of treatment failure when the patient had recovered from toxicity and was ready for further therapy. Topotecan proved to be effective in achieving a remission but attempts to optimize survival by reducing pre-transplant MRD levels 15 were not successful. Unexpectedly the leukemia remained sensitive to topotecan after relapse.
This report confirms that an effective treatment option(s) can be identified and validated for some high risk ALL patients without targetable molecular abnormalities. A PDX allowed us to rule out a potential-targeted therapy (ATRA) and to select between two different, apparently effective salvage regimens. Furthermore, excellent disease control was achieved despite prior drug resistance. Despite a third relapse, the patient responded to additional topotecan with acceptable toxicity and good quality of life.
